Key Highlights

  • Gyre Therapeutics shares were up 11.96 percent to USD 5.10 in pre-market trading on November 2, 2026.
  • No company announcement dated late October to November 2, 2026 was identified as a catalyst.
  • Second quarter 2026 Revenue was USD 29.1 million, down 2 percent from USD 29.7 million a year earlier.
  • Cash and investments totaled USD 103.2 million at June 30, 2026.
  • Full-year 2026 revenue guidance of USD 100.5 million to USD 111.0 million was affirmed on August 7, 2026.

What Moved Gyre Pre-Market

Gyre Therapeutics (NASDAQ:GYRE) was up 11.96 percent to USD 5.10 in pre-market trading on November 2, 2026. The move came without a clearly identified trigger.

No press release, regulatory filing or trial readout from the company dated between late October and November 2, 2026 was found. A market data page published November 1, 2026 described the shares as Gapping down, so the pre-market gain may partly reflect a rebound. That is a market observation, not a company statement.

The Catalyst Question

Absent a company announcement, the rise looks consistent with ordinary momentum in small-cap biotech names. ## Business Background and Recent Results

Gyre is a biopharmaceutical company focused on organ fibrosis. Its main commercial product is ETUARY, a pirfenidone treatment for idiopathic pulmonary fibrosis sold in China through its majority-owned subsidiary.

According to a company press release dated August 7, 2026, second quarter revenue was USD 29.1 million, with ETUARY contributing USD 28.0 million versus USD 23.5 million a year earlier. The net loss widened to USD 14.3 million from USD 2.2 million, and the company cited Transaction Costs and higher operating spending after the Cullgen deal closed on May 4, 2026.

On the pipeline, the company said China's drug regulator accepted the new drug application for hydronidone in May 2026, for liver fibrosis caused by chronic hepatitis B, after priority review status in March 2026. A Phase 3 pneumoconiosis trial of ETUARY enrolled 272 patients, with the final patient expected to complete the study by the fourth quarter of 2026.

Balance Sheet and Risks

Cash, deposits and investments stood at USD 103.2 million on June 30, 2026, down USD 12.9 million from USD 116.1 million at December 31, 2025. The company reported an operating loss of USD 33.3 million for the first half of 2026.

The Astellas collaboration ended in March 2026, which reduced collaboration revenue by USD 3.0 million in the second quarter. The company noted that a planned Merger between Cullgen and another company was terminated in February 2026.

What to Watch Next

The next items are the third quarter 2026 financial results and any update on the hydronidone review in China. Completion of the pneumoconiosis trial by the fourth quarter of 2026 is another milestone the company has flagged.